Intervacc Dividends and Buybacks

Dividend criteria checks 0/6

Intervacc does not have a record of paying a dividend.

Key information

n/a

Dividend yield

Buyback Yield

Total Shareholder Yield	0%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Dec 15

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

Jun 01

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

May 17

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

Feb 28

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Feb 01

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Jan 06

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Dec 10

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if IVACC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IVACC's dividend payments have been increasing.

Dividend Yield vs Market

Intervacc Dividend Yield vs Market

How does IVACC dividend yield compare to the market?
Segment	Dividend Yield
Company (IVACC)	n/a
Market Bottom 25% (SE)	1.6%
Market Top 25% (SE)	4.9%
Industry Average (Biotechs)	1.6%
Analyst forecast (IVACC) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate IVACC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IVACC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate IVACC's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IVACC has not reported any payouts.

Intervacc Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023)

Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023)

Is Intervacc (STO:IVACC) In A Good Position To Invest In Growth?

First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023)

Intervacc AB (Publ) Announces Board Appointments

Intervacc AB (publ) Announces Changes in the Nomination Committee

Jonas Sohlman Appoints as New CEO for Intervacc AB (publ)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) to Report Q1, 2024 Results on May 23, 2024

Intervacc AB (publ) Announces Changes in the Nomination Committee

No independent directors

Intervacc AB (publ) Announces Executive Changes

New major risk - Share price stability

Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022)

Intervacc AB (publ) Announces Composition of Nomination Committee

We're Keeping An Eye On Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022)

Intervacc AB (publ) Announces Executive Changes

Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova

Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.

Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member

The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months

Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months

First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022)

Forecast breakeven date pushed back to 2025

We Think Intervacc (STO:IVACC) Needs To Drive Business Growth Carefully

Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021)

Forecast breakeven date pushed back to 2024

Intervacc AB (publ) to Report Fiscal Year 2022 Results on Apr 06, 2023

Intervacc AB (Publ) Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021)

Intervacc AB (Publ) Announces First Batch of Strangvac for Sale in Germany, France, Austria, Belgium, Luxemburg and the Netherlands Released

We're Not Very Worried About Intervacc's (STO:IVACC) Cash Burn Rate

Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021)

Intervacc AB (Publ) Announces That Strangvac Is Now Available for Sale in the Uk

Intervacc AB (Publ) Elects Michela De Carli as Board Member At the Annual General Meeting Held on June 14, 2022

Intervacc Announces Strangvac, A Vaccine Against Equine Strangles, Available for Sale in Denmark

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Intervacc AB (publ) Announces Initiation of a Proof-Of-Concept Study to Measure the Effectiveness of a Vaccine to Protect Dairy Cows Against Mastitis

We're Not Worried About Intervacc's (STO:IVACC) Cash Burn

Ntervacc AB (Publ) Announces Positive Results from A Proof-Of-Concept Study to Develop A Vaccine Against Streptococcus Suis Infection in Pigs

Full year 2021 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2023

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Intervacc AB (publ), Annual General Meeting, Jun 14, 2022

Intervacc Applies for A Permit for Sale and Distribution of Strangvac in the U.S

Intervacc Applies for Supplementary Protection Certificates for Strangvac in Key European Markets

Here's Why We're Not At All Concerned With Intervacc's (STO:IVACC) Cash Burn Situation

Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020)

Intervacc Receives Confirmation of a Positive Outcome for Strangvac, a Vaccine against Equine Strangles, from the VMD in the UK

Intervacc AB Receives Positive CVMP Opinion for Strangvac, A Vaccine Against Equine Strangles, in the EU

Independent Director Newton Aguiar has left the company

It Looks Like The CEO Of Intervacc AB (publ) (STO:IVACC) May Be Underpaid Compared To Peers

First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020)

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

Independent Director recently sold kr29m worth of stock

Intervacc AB (publ) (STO:IVACC) Insiders Have Been Selling

New 90-day high: kr76.60

Full year 2020 earnings released: kr0.54 loss per share (vs kr0.71 loss in FY 2019)

Revenue and earnings miss expectations

Intervacc AB (publ) to Report Q2, 2021 Results on Sep 03, 2021

Intervacc AB (publ), Annual General Meeting, Jun 09, 2021

New 90-day high: kr54.80

We Think Intervacc (STO:IVACC) Can Easily Afford To Drive Business Growth

When Will Intervacc AB (publ) (STO:IVACC) Become Profitable?

Is Intervacc AB (publ)'s (STO:IVACC) Shareholder Ownership Skewed Towards Insiders?

Intervacc AB (Publ) Appoints Emma Hartman as Global Product Manager for Strangvac

Third quarter 2020 earnings released: kr0.13 loss per share

Revenue and earnings miss expectations

New 90-day high: kr48.80

New 90-day high: kr40.00

First half earnings released

New 90-day high - kr35.25